Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal Triamcinolone Acetonide in Diabetic Macular Edema (CAPE)
NCT05512962Phase 2Completed
- Sponsor
- Oxular Limited
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of triamcinolone acetonide in diabetic macular edema (DME), sponsored by Oxular Limited. Started Aug 2022; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05512962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512962.